Clinical trials
Locally Advanced or Metastatic Solid Tumors clinical trials
Below are recruiting locally advanced or metastatic solid tumors clinical trials, each written for real people, not researchers. We’re tracking 3,336 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07348211RecruitingPhase 1
Study of SIM0610 for advanced solid tumors
This trial tests a new drug called SIM0610 for people with advanced solid tumors that have stopped responding to standard treatments. The study aims to see if the drug is safe and effective.
Chongqing, Chongqing MunicipalityAges 18 years+ - NCT06730386RecruitingPhase 1
Trial of AK138D1 for advanced solid tumors
This trial tests a new drug called AK138D1 for people with advanced solid tumors that have not responded to or can't tolerate standard treatments. The goal is to see if it is safe and effective.
Blacktown, New South WalesAges 18–75 - NCT07288632Recruiting
Lung cancer gene test and blood clot risk study
This study looks at whether certain gene profiles in advanced lung cancer affect the risk of blood clots. It may help doctors better understand and prevent clots in people starting new cancer treatment.
Perugia, PerugiaAges 18 years+ - NCT06846437RecruitingPhase 3
New drug JSKN003 vs. Kadcyla for HER2-positive advanced breast cancer
This trial compares a new targeted therapy (JSKN003) against Kadcyla (T-DM1) for people with HER2-positive breast cancer that has advanced or spread. Both drugs work by attaching a chemotherapy directly to HER2-positive cancer cells, and the study aims to see if the new drug works better or has fewer side effects.
ShanghaiAges 18 years+ - NCT07250386RecruitingPhase 1
CEA-targeted CAR-T therapy for advanced solid tumors
This trial tests a new CAR-T cell therapy that targets CEA, a protein found on certain cancer cells. It's for people with advanced solid tumors like lung or breast cancer who have not responded to other treatments.
Hangzhou, ZhejiangAges 18 years+ - NCT07246863RecruitingPhase 2
Testing visugromab and nivolumab with or without docetaxel for advanced lung cancer
This trial tests a new combination of drugs (visugromab, nivolumab, and possibly docetaxel) for people with advanced non-squamous non-small cell lung cancer that worsened after one prior treatment with an immunotherapy. The goal is to see if the combination helps control the cancer better.
Birmingham, AlabamaAges 18 years+ - NCT07241793RecruitingPhase 2
Trastuzumab rezetecan with or without immunotherapy for advanced bladder cancer
This trial tests a new drug combination for people with advanced bladder cancer that has a protein called HER2 on its surface. It may help those whose cancer has spread or cannot be removed with surgery. The study looks at the drug given alone or with an immunotherapy.
Guangzhou, GuangdongAges 18 years+ - NCT07231458RecruitingPhase 1
Testing a new immunotherapy with pembrolizumab for advanced solid tumors
This trial tests ABX-001, a new immunotherapy, alone or with pembrolizumab, for people with advanced solid tumors that have not responded to or cannot tolerate standard treatments. It may help if your tumor has become resistant to previous immunotherapies.
BerlinAges 18 years+ - NCT06196736RecruitingPhase 3
Comparing a new drug to chemo for advanced bladder cancer
This trial tests a new drug, 9MW2821, against standard chemotherapy for people with advanced bladder cancer that has gotten worse after previous treatments. It aims to see if the new drug works better.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07207707RecruitingPhase 1
KQB548 for advanced solid tumors with KRAS G12D mutation
This trial tests a new drug called KQB548 for people with certain advanced cancers (pancreatic, colorectal, or lung) that have a specific genetic change called KRAS G12D. It's for those whose cancer has continued to grow despite previous treatments.
La Jolla, CaliforniaAges 18 years+ - NCT07195513Recruiting
Helping advanced cancer patients connect to palliative care via electronic reporting
This trial uses electronic surveys to identify symptoms and unmet needs in people with advanced cancer, then connects them to palliative care services. It aims to improve quality of life by making sure patients get the extra support they need.
Lebanon, New HampshireAges 18 years+ - NCT06950086RecruitingPhase 1/Phase 2
TYK-00540 tablets for advanced solid tumors
This trial tests a new tablet, TYK-00540, alone or with another drug, for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug can shrink tumors or slow their growth.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07182721RecruitingPhase 2
Study of SKB264 plus Inetetamab for advanced HER2+ breast cancer after T-DXd
This trial is testing a combination of two targeted therapies, SKB264 and Inetetamab, for people with advanced HER2-positive breast cancer that has kept growing after treatment with T-DXd and other HER2-targeted therapies. The goal is to see if this new combination can shrink tumors or slow the cancer's growth.
ShanghaiAges 18 years+ - NCT07173868Recruiting
PET scans for advanced breast cancer treatment planning
This trial tests whether a special PET scan (FDG PET-CT) can better track how well treatment is working for people with advanced breast cancer. It may help doctors choose the best therapy and monitor response over time.
Seoul, Gannam-guAges 19 years+ - NCT07164313RecruitingPhase 1
ZW251 for advanced solid tumors
This trial is testing a new drug called ZW251 for people with advanced liver cancer (hepatocellular carcinoma), non-small cell lung cancer, or germ cell tumors that have spread or cannot be removed by surgery. It aims to see if the drug is safe and effective.
San Francisco, CaliforniaAges 18 years+ - NCT07132190RecruitingPhase 2
Radiation for growing brain tumors with same-day planning
This study tests whether a precise, one-day radiation treatment for brain tumors that are growing or in tricky spots can be effective with a smaller safety margin. It's designed for people whose brain tumors are changing quickly or sitting near areas of swelling or recent surgery.
Boston, MassachusettsAges 18 years+ - NCT07098988RecruitingPhase 2
Visugromab plus standard chemo-immunotherapy for lung cancer
This trial tests an experimental drug called visugromab added to standard chemotherapy and immunotherapy for people newly diagnosed with advanced non-squamous lung cancer. It aims to see if the combination works better than standard treatment alone.
Birmingham, AlabamaAges 18 years+ - NCT06958679RecruitingPhase 1
Study of SYS6005 for advanced solid tumors and lymphomas
This study tests a new drug (SYS6005) that targets a protein called ROR1 on certain cancer cells. It is for people with advanced solid tumors or B-cell lymphomas that have stopped responding to other treatments.
TianjinAges 18 years+ - NCT07085767RecruitingPhase 3
Palazestrant and ribociclib for first-line advanced breast cancer
This trial tests a new drug (palazestrant) combined with ribociclib for people with a common type of advanced breast cancer that is estrogen receptor-positive and HER2-negative. You may qualify if you haven't had treatment for advanced disease and your cancer has either just been found or came back long after completing hormone therapy.
Hot Springs, ArkansasAges 18 years+ - NCT07084558Recruiting
Testing treatment guided by tumor DNA for hormone positive breast cancer
This trial tests whether using a blood test (circulating tumor DNA) can help guide chemo and hormone therapy for early-stage, hormone receptor positive and HER2 negative breast cancer. The goal is to tailor treatment to your tumor's response, potentially reducing unnecessary side effects.
Vienna, AustriaAges 18–100 - NCT07081984RecruitingPhase 1
Testing TI-0093 for advanced HPV-16 positive cancers
This study tests a new drug, TI-0093, for people with HPV‑16 positive solid tumors (like head and neck or cervical cancer) that have come back or spread after standard treatments. The goal is to see if the drug can help shrink tumors or slow their growth.
ShanghaiAges 18–75 - NCT07067138Recruiting
Genetic testing to guide treatment for advanced breast cancer
This study looks at the genes in your cancer to find a treatment that might work better for you. It tests your tumor sample to match you with a drug that targets your cancer's specific weaknesses.
Bethesda, MarylandAges 18–120 - NCT07073534RecruitingPhase 1/Phase 2
A study of two drugs for advanced solid tumors
This trial tests two drugs combined—SHR-1501 and adbelizumab—for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if the combination is safe and effective.
Guangzhou, GuangdongAges 18–75 - NCT07071337RecruitingPhase 3
Study of SKB264 vs chemo for HR+/HER2- breast cancer after hormone therapy
This trial tests a new drug, SKB264, against standard chemotherapy for people with a common type of breast cancer (HR+/HER2-) that has spread and stopped responding to hormone therapy. It may offer a new option if you haven't had chemotherapy for advanced disease.
Beijing, Beijing MunicipalityAges 18–75
Hear when a new Locally Advanced or Metastatic Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for locally advanced or metastatic solid tumors?
- Yes. Clin2 currently lists 3,336 recruiting locally advanced or metastatic solid tumors studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a locally advanced or metastatic solid tumors trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a locally advanced or metastatic solid tumors trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Locally Advanced (Unresectable) or Metastatic Solid Tumors
- Locally Advanced/Metastatic Solid Tumors
- Advanced or Metastatic Solid Tumors
- Advanced/Metastatic Solid Tumors
- Locally Advanced or Metastatic Breast Cancer
- Locally Advanced Solid Tumor
- Locally Advanced Malignant Solid Neoplasm
- Locally Advanced or Metastatic Non-small Cell Lung Cancer
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.